Following the presentation of the OPTIMA1 trial’s first-results at ASCO, chief investigator Prof. Rob Stein returns for a deeper discussion of the study that showed more than two-thirds of node-positive patients who previously might have received chemotherapy can now safely avoid it based on the Prosigna test results.
During this webinar, Prof. Rob Stein will present study results and, together with Kelly Marcom, Veracyte breast cancer medical director, will discuss the potential impact of these findings on future treatment decisions for high-risk patients.
Speakers
Rob Stein, Ph.D., FRCP
Honorary Professor of Breast Oncology, University College London
Rob Stein is an honorary professor of breast oncology at University College London and an honorary consultant in medical oncology at UCLH. A Cambridge-trained physician-scientist, he spent more than 20 years as a full time NHS consultant specializing in the systemic treatment of early and advanced breast cancer.
He is widely recognized for his leadership in clinical trials, including serving as chief investigator of the OPTIMA program, and has contributed to numerous national and international studies. Stein has authored more than 90 peer reviewed publications and has held key roles across major UK cancer research committees.
Medical Director, Breast Cancer, Veracyte
Kelly Marcom is the medical director for breast cancer at Veracyte. He was previously professor of medicine in the Division of Medical Oncology at Duke Cancer Center, where he spent more than two decades as a clinician, researcher, and educator. A board-certified medical oncologist, Marcom specialized in breast cancer, cancer genetics, and precision oncology, with a strong focus on translating genomic and molecular insights into personalized treatment strategies.
Marcom has authored more than 200 peer-reviewed publications and has played a key role in national and international clinical trials, guideline development, and multidisciplinary cancer care.
Tags
Live
Prosigna Breast